Author name: Leonardo Arias

En los últimos años, el deshielo acelerado del Ártico y de regiones permafrost ha reavivado una pregunta tan fascinante como inquietante: ¿es posible que la humanidad llegue a “resucitar” virus o microorganismos que han permanecido congelados durante decenas d …

Cuando hoy un laboratorio determina la composición de una molécula orgánica en cuestión de microgramos, rara vez se recuerda que ese nivel de precisión fue, hace un siglo, un desafío monumental. La revolución llegó de la mano de Fritz Pregl, un …

  Recuerdo cuando La resistencia ludita llegó a mis manos a mediados de 2025. Como ávido lector de ciencia ficción, estaba entusiasmado pero escéptico: ¿otra novela más sobre inteligencia artificial y futuros distópicos? Sin embargo, desde las …

Experts suggest the FDA’s Advanced Manufacturing Technologies designation could be a lifeline for improving production processes for approved cell and gene therapies.

The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.

Hospitals lambasted the final rule as inadequate, arguing the sector is facing significant financial pressures.

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.

Funding through the third quarter surpassed last year’s total, according to PitchBook. Meanwhile, average deal sizes are skyrocketing as high valuations — especially for AI startups — drive larger rounds.